Veterinary Cancer Therapeutics Market: By Product (Chemotherapeutic Agent, Vaccine, Others), By Cancer (Mast Cell Tumors, Lymphoma, Insulinomas, Chondrosarcoma, Others), By Species (Bovine, Porcine, Cats, Dogs, Others) and Region  

Purchase Option

$ 4400
$ 6600
$ 8900

Veterinary Cancer Therapeutics Market size was valued at USD 278.2 million in 2022 and is expected to grow at a CAGR of 11.6% from 2023 to 2029. The global market provides a detailed overview of the Veterinary Cancer Therapeutics market, and that can be segmented by product, by cancer, and by Species. By product, the Veterinary Cancer Therapeutics market has been segmented into Chemotherapeutic Agents, Vaccines, and Others. The chemotherapy segment is likely to be the largest and fastest-growing segment in terms of product. The rise of this segment is mainly due to the growing number of chemotherapeutic events accepted by surgeons owing to the several advantages. As per the oncology guidelines by AAHA, chemotherapy is a frequently used mode of veterinary oncology treatment in veterinary cancer medication.

Moreover, other chemotherapy approaches for example conventional, targeted chemotherapy such as Tyrosine Kinase Inhibitors and metronomic are accepted by small animal doctors. Based on Cancer, the Veterinary Cancer Therapeutics market is segmented into Mast Cell Tumors, Lymphoma, Insulinomas, Chondrosarcoma, and Others. Among these, the lymphoma cancer segment is expected to have the fastest-growing market during the forecast period 2022-2028. The rise of this segment is mainly due to the growing number of the pet population, particularly canines, being suffered by the disease. As per a PubMed report, an assessed incidence rate of 20-100 cases per 100,000 dogs suffered from this disease. Based on the Species, the Veterinary Cancer Therapeutics market is segmented into Bovine, Porcine, Cats, Dogs, and Others. The dogs segment is expected to have a significant share in 2021. The rise of this segment is mainly because of the increasing prevalence of cancer in the dog population and growing life expectancy. Moreover, the rising incidence of cancer in this populace has further involved scientists in comparative veterinary oncology treatment with many clinical trials on dogs as a biological model.

Veterinary Cancer Therapeutics Market Key Developments:
  • In September 2022, CureLab Veterinary launched an equity crowdfunding campaign to transform medicine for dogs, cats, and horses
  • In June 2022, Ankyra Therapeutics announced a research partnership with the College of Veterinary Medicine.

Global Veterinary Cancer Therapeutics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

11.6%

Largest Market

North America

Fastest Growing Market

North America
Veterinary Cancer Therapeutics Market Dynamics

The rise in the prevalence of cancer in animals, particularly in pets, along with the rise in R&D investment by businesses to generate cancer therapeutics, such as chemotherapeutic agents and preventive vaccines, are anticipated to propel the market growth over the forecast years. Moreover, an increase in animal health expenditure and a vigorous animal cancer pipeline are burgeoning the market growth over the forecast years.

Key Features of the Reports

  • The veterinary cancer therapeutics market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Veterinary Cancer Therapeutics Market Segmentation

By Product
  • Chemotherapeutic Agent
  • Vaccine
  • Others
By Cancer
  • Mast Cell Tumors
  • Lymphoma
  • Insulinomas
  • Chondrosarcoma
  • Others
By Species
  • Bovine
  • Porcine
  • Cats
  • Dogs
  • Others
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The veterinary cancer therapeutics market is projected to expand at a CAGR of 11.6% during the forecast period

Merial (C.H. BoehringerSohn AG &Ko. KG) (Germany), Zoetis Inc. (U.S.), AB Science (France), Aratana Therapeutics (U.S.), Oasmia Pharmaceutical (Sweden), Vetivax (U.S.), Regeneus (Australia)

North America is the fastest-growing region for veterinary cancer therapeutics market

1.Executive Summary
2.Global Veterinary Cancer Therapeutics Market Introduction 
2.1.Global Veterinary Cancer Therapeutics Market  - Taxonomy
2.2.Global Veterinary Cancer Therapeutics Market  - Definitions
2.2.1. By Product Type
2.2.2. By Cancer
2.2.3. By Species
2.2.4. By Region
3.Global Veterinary Cancer Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Veterinary Cancer Therapeutics Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Veterinary Cancer Therapeutics Market  By Product Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Chemotherapeutic Agent
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Vaccine
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Others
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Veterinary Cancer Therapeutics Market  By Cancer, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Mast Cell Tumors
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Lymphoma
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Insulinomas
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Chondrosarcoma
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Veterinary Cancer Therapeutics Market  By Species, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Bovine
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Porcine
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Cats
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Dogs
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Others
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.Global Veterinary Cancer Therapeutics Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Veterinary Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Chemotherapeutic Agent
9.1.2.Vaccine
9.1.3.Others
9.2.  Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Mast Cell Tumors
9.2.2.Lymphoma
9.2.3.Insulinomas
9.2.4.Chondrosarcoma
9.2.5.Others
9.3.  Species Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Bovine
9.3.2.Porcine
9.3.3.Cats
9.3.4.Dogs
9.3.5.Others
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Veterinary Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Chemotherapeutic Agent
10.1.2.Vaccine
10.1.3.Others
10.2.  Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Mast Cell Tumors
10.2.2.Lymphoma
10.2.3.Insulinomas
10.2.4.Chondrosarcoma
10.2.5.Others
10.3.  Species Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Bovine
10.3.2.Porcine
10.3.3.Cats
10.3.4.Dogs
10.3.5.Others
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Veterinary Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Chemotherapeutic Agent
11.1.2.Vaccine
11.1.3.Others
11.2.  Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Mast Cell Tumors
11.2.2.Lymphoma
11.2.3.Insulinomas
11.2.4.Chondrosarcoma
11.2.5.Others
11.3.  Species Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Bovine
11.3.2.Porcine
11.3.3.Cats
11.3.4.Dogs
11.3.5.Others
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Veterinary Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Chemotherapeutic Agent
12.1.2.Vaccine
12.1.3.Others
12.2.  Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Mast Cell Tumors
12.2.2.Lymphoma
12.2.3.Insulinomas
12.2.4.Chondrosarcoma
12.2.5.Others
12.3.  Species Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Bovine
12.3.2.Porcine
12.3.3.Cats
12.3.4.Dogs
12.3.5.Others
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Veterinary Cancer Therapeutics Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Product Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Chemotherapeutic Agent
13.1.2.Vaccine
13.1.3.Others
13.2.  Cancer Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Mast Cell Tumors
13.2.2.Lymphoma
13.2.3.Insulinomas
13.2.4.Chondrosarcoma
13.2.5.Others
13.3.  Species Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Bovine
13.3.2.Porcine
13.3.3.Cats
13.3.4.Dogs
13.3.5.Others
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.AB Science (France)
14.2.2.Aratana Therapeutics (U.S.)
14.2.3.Oasmia Pharmaceutical (Sweden)
14.2.4.Vetivax (U.S.)
14.2.5.Regeneus (Australia)
14.2.6.Zoetis Inc. (U.S.)
15. Research Methodology 
16. Appendix and Abbreviations 
  • Merial (C.H. BoehringerSohn AG &Ko. KG) (Germany)
  • Zoetis Inc. (U.S.)
  • AB Science (France)
  • Aratana Therapeutics (U.S.)
  • Oasmia Pharmaceutical (Sweden)
  • Vetivax (U.S.)
  • Regeneus (Australia)

Adjacent Markets